Imugene Limited (ASX:IMU)

Australia · Delayed Price · Currency is AUD

0.1350

-0.0050 (-3.57%)

At close: Mar 31, 2026

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Research and Development of Oncolytic Immunotherapies	4.40M	4.97M	11.78M	12.97M	7.23M
Research and Development of Oncolytic Immunotherapies Growth	-11.53%	-57.80%	-9.19%	79.35%	74.94%
Total	4.40M	4.97M	11.78M	12.97M	7.23M
Total Growth	-11.53%	-57.80%	-9.19%	79.35%	74.94%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	Jun '18 Jun 30, 2018	Jun '17 Jun 30, 2017	Jun '16 Jun 30, 2016
Australia	4.40M	4.97M	11.78M	12.97M	7.23M
Australia Growth	-11.53%	-57.80%	-9.19%	79.35%	74.94%
Total	4.40M	4.97M	11.78M	12.97M	7.23M
Total Growth	-11.53%	-57.80%	-9.19%	79.35%	74.94%

Source: S&P Global Market Intelligence.